UK Grants EAMS Positive Opinion to Atezolizumab Combo in Frontline TNBC

March 14, 2019 – The United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted an Early Access to Medicines Scheme (EAMS) positive scientific opinion to atezolizumab in combination with nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC). The EAMS is designed to give patients with life-threatening or seriously debilitating conditions access to … (leggi tutto)